JP2009515831A5 - - Google Patents

Download PDF

Info

Publication number
JP2009515831A5
JP2009515831A5 JP2008537233A JP2008537233A JP2009515831A5 JP 2009515831 A5 JP2009515831 A5 JP 2009515831A5 JP 2008537233 A JP2008537233 A JP 2008537233A JP 2008537233 A JP2008537233 A JP 2008537233A JP 2009515831 A5 JP2009515831 A5 JP 2009515831A5
Authority
JP
Japan
Prior art keywords
antigen
antigens
immunogenic composition
combination
pestis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008537233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009515831A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2006/003843 external-priority patent/WO2007049155A2/en
Publication of JP2009515831A publication Critical patent/JP2009515831A/ja
Publication of JP2009515831A5 publication Critical patent/JP2009515831A5/ja
Pending legal-status Critical Current

Links

JP2008537233A 2005-10-25 2006-10-25 ペスト菌(Yersiniapestis)抗原を含む組成物 Pending JP2009515831A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73018205P 2005-10-25 2005-10-25
US81783806P 2006-06-30 2006-06-30
PCT/IB2006/003843 WO2007049155A2 (en) 2005-10-25 2006-10-25 Compositions comprising yersinia pestis antigens

Publications (2)

Publication Number Publication Date
JP2009515831A JP2009515831A (ja) 2009-04-16
JP2009515831A5 true JP2009515831A5 (OSRAM) 2010-11-11

Family

ID=37968196

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008537233A Pending JP2009515831A (ja) 2005-10-25 2006-10-25 ペスト菌(Yersiniapestis)抗原を含む組成物

Country Status (6)

Country Link
US (1) US7776336B2 (OSRAM)
EP (1) EP1954306A2 (OSRAM)
JP (1) JP2009515831A (OSRAM)
AU (1) AU2006307602A1 (OSRAM)
CA (1) CA2627302A1 (OSRAM)
WO (1) WO2007049155A2 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
GB0525213D0 (en) * 2005-12-12 2006-01-18 Secr Defence Vaccine
US10174100B1 (en) * 2006-11-06 2019-01-08 Microvax, Llc Multivalent DNA composition for Yersinia pestis
GB0717187D0 (en) * 2007-09-04 2007-10-17 Novartis Ag Compositions comprising yersinia pestis antigens
US8722046B2 (en) * 2009-04-08 2014-05-13 The United States Of America As Represented By The Secretary Of The Army Human monoclonal antibodies protective against bubonic plague
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
AU2010324731B2 (en) * 2009-11-24 2017-02-23 Takeda Vaccines, Inc. Compositions, methods and uses for expression of enterobacterium-associated peptides
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
PL2591114T3 (pl) 2010-07-06 2017-08-31 Glaxosmithkline Biologicals Sa Immunizacja dużych ssaków małymi dawkami rna
FI4005592T3 (fi) 2010-07-06 2023-01-13 Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
AU2011276234B2 (en) 2010-07-06 2016-02-25 Glaxosmithkline Biologicals S.A. Liposomes with lipids having an advantageous pKa- value for RNA delivery
AU2011295938B2 (en) 2010-08-31 2016-01-14 Glaxosmithkline Biologicals S.A. Lipids suitable for liposomal delivery of protein-coding RNA
PT3981427T (pt) 2010-08-31 2022-06-27 Glaxosmithkline Biologicals Sa Lipossomas peguilados para entrega de arn codificador de imunogénio
TR201903651T4 (tr) 2010-10-11 2019-04-22 Glaxosmithkline Biologicals Sa Antijen uygulama platformları.
EP2667852B1 (en) 2011-01-27 2016-11-09 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with crystallisation inhibitors
EP2688590B1 (en) 2011-03-24 2020-02-12 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with phospholipids
CN103764121A (zh) 2011-07-06 2014-04-30 诺华股份有限公司 用于递送rna分子的具有有用n:p比的脂质体
EP2729165B1 (en) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
BR112014004607A2 (pt) 2011-08-31 2017-03-21 Novartis Ag lipossomas peguilados para entrega de rna codificado imunogênico
EP3400960A1 (en) 2012-09-18 2018-11-14 GlaxoSmithKline Biologicals S.A. Outer membrane vesicles
EA201891018A1 (ru) 2013-03-08 2018-09-28 Новартис Аг Липиды и липидные композиции для доставки активных агентов
ES2774968T3 (es) 2013-12-19 2020-07-23 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
EP4019506A1 (en) 2013-12-19 2022-06-29 Novartis AG Lipids and lipid compositions for the delivery of active agents
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
ES2969956T3 (es) 2014-09-05 2024-05-23 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
BR112023006710A2 (pt) 2020-10-14 2023-10-03 George Mason Res Foundation Inc Métodos de fabricação de nanopartícula lipídica e composições derivadas da mesma
CN112609013A (zh) * 2021-01-12 2021-04-06 深圳市赛格诺生物科技有限公司 一种用于检测鼠疫耶尔森菌的荧光pcr试剂及方法
EP4387597A1 (en) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
WO2023021421A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
GB202303019D0 (en) 2023-03-01 2023-04-12 Glaxosmithkline Biologicals Sa Method of lyophilisation
GB202311382D0 (en) 2023-07-25 2023-09-06 Glaxosmithkline Biologicals Sa Lyophilised compostion

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0525213D0 (en) 2005-12-12 2006-01-18 Secr Defence Vaccine

Similar Documents

Publication Publication Date Title
JP2009515831A5 (OSRAM)
Shin et al. COVID-19 vaccine development and a potential nanomaterial path forward
JP2012501959A5 (OSRAM)
JP2006526414A5 (OSRAM)
DE60329106D1 (de) Ghrelin-träger-konjugate
JP2010162023A5 (OSRAM)
WO2006045796A3 (en) Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof
WO2008057235A3 (en) Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
JP2010524489A5 (OSRAM)
WO2006063974A3 (en) Il-15 antigen arrays and uses thereof
JP2017507117A5 (OSRAM)
PL369863A1 (en) Antigen arrays for treatment of allergic eosinophilic diseases
AU2003246373A8 (en) Recombinant measles viruses expressing epitopes of antigens of rna viruses - use for the preparation of vaccine compositions
JP2009504654A5 (OSRAM)
WO2003039225A3 (en) Antigen arrays comprising rankl for treatment of bone disease
JP2011517938A5 (OSRAM)
JP2010532656A5 (OSRAM)
Kovalenko et al. Vaccine candidate against COVID-19 based on structurally modified plant virus as an adjuvant
JP2010506926A5 (OSRAM)
JP2015529677A5 (OSRAM)
WO2001096370A3 (en) Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof
Nuzzaci et al. In vitro stability of Cucumber mosaic virus nanoparticles carrying a Hepatitis C virus-derived epitope under simulated gastrointestinal conditions and in vivo efficacy of an edible vaccine
JP2006523185A5 (OSRAM)
CN102464721B (zh) 针对人肠道病毒71型的重组广谱性疫苗
WO2003059386A3 (en) Prion protein carrier-conjugates